24. Mhando L, Jande MB, Liwa A, Mwita S, Marwa KJ. Awareness raising and identification of falsified medicines Intanzania: a look at antimalarial medicines. Hindawi Publ Corp Advan Public Health. (2016) 2016:6254157. doi: 10.1155/2016/6254157 The pharmaceutical industry should be fully involved in the fight against falsified medicines. One reason for the spread of SF drugs is the high price of certain groups of drugs [63]. The pharmaceutical industry should take the lead in making its prices more affordable, especially in low- and middle-income countries. The pharmaceutical industry should also launch awareness campaigns to increase public and health system knowledge about the presence of SF products and their health risks.
Technologies are essential tools to secure the legitimate supply chain and ensure the authenticity of medicines. Strong national regulatory frameworks are essential to ensure safe and genuine medicines. These frameworks give regulators and law enforcement authorities the powers they need to combat falsified medicines that thrive where regulatory oversight and enforcement are weak. The WHO has even pointed out that weak or non-existent national regulatory systems are a key factor facilitating the falsification of medicines. The EMA coordinates the exchange of information on notifications of falsified medicinal products in relation to centrally authorised medicinal products and provides information to the national competent authorities of the EU Member States responsible for investigating the supply chain and deciding on marketing measures. For more information, see Falsified medicines: reporting requirements. These technologies are visible to the naked eye and require end-users and healthcare providers to become familiar with them. They are often embedded in tamper-evident features, such as labels that transfer “EMPTY” to the surface of the container when peeled off.
This avoids the reuse of original components for counterfeit products. Another example is holograms, which usually contain images with the illusion of a three-dimensional construction, thus combining three-layer security features. Broadus RN: Towards a definition of “bibliometrics”. Scientometrics 1987, 12(5–6):373–379. 14. Tadeg H, Berhane Y. Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries. East Afr J Public Health. (2012) 9:85–9. nIt was established to protect public health and promote access to affordable, safe, effective and high-quality medical devices through effective collaboration between Member States and WHO to prevent and control substandard and falsified medical devices and related activities. The logo will allow patients and consumers to identify licensed online pharmacies and authorized retailers that offer genuine and approved drugs. A click on the logo leads to the websites of national regulatory authorities, which list all online pharmacies and authorized distributors operating legally in their respective countries.
Table 4 shows the rate of identification of counterfeit medicines by demographic factors. Participants who were male (p = 0.048), older (p = 0.006), single (p = 0.012) and highly educated had a significantly higher rate of counterfeiting. In addition, there was a significant correlation between geographic areas and the rate of identification of counterfeit medicines (p = 0.021). Participants from the Middle East had a significantly lower rate of identification of counterfeit medicines than participants from other regions. Manufacturers upload the information contained in the unique identifier of each medicinal product to an EU central repository. The end-to-end verification system for medicinal products is part of an end-to-end verification system for medicinal products introduced by the Regulation. Depending on the source of the drug, wholesalers must also scan drugs at different stages of the supply chain to verify their authenticity. Pharmacies and hospitals then scan each drug at the end of the supply chain to verify its authenticity and remove it from the repository before dispensing it to patients. 8.
Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ open. (2013) 3:E002923. doi: 10.1136/bmjopen-2013-002923 A bibliometric approach was chosen, using terms such as false, false, false, inferior and others. No language restrictions were applied. The survey period was from 1900 to 2020. The search strategy was validated and implemented using the Scopus database. Suthar AB, Coggin W, Raizes E. Antimicrobial resistance and substandard and counterfeit medicines: the case of HIV/AIDS. The Journal of Infectious Diseases.
2019;219(4):672. Two groundbreaking studies provide insightful data and analysis on the global challenges of falsified medicines. The first, led by University College London School of Pharmacy and international research agency Matrix Insight, highlights the possibilities for a more coordinated international response to falsified medicines. The report examines the growing recognition by governments of the importance of preventing counterfeiting and highlights the need for greater cooperation among all stakeholders. The report concludes that more investment is needed both to quantify counterfeits and to alert potentially dangerous products early when they are detected in legitimate supply chains.
